A Phase III, International, Randomised, Double Blind, Parallel-Group Study to Assess the Efficacy of Zactima Versus Tarceva in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Failure of at Least One Prior Chemotherapy.

Trial Profile

A Phase III, International, Randomised, Double Blind, Parallel-Group Study to Assess the Efficacy of Zactima Versus Tarceva in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Failure of at Least One Prior Chemotherapy.

Completed
Phase of Trial: Phase III

Latest Information Update: 10 Mar 2017

At a glance

  • Drugs Vandetanib (Primary) ; Erlotinib
  • Indications Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms ZEST
  • Sponsors Sanofi Genzyme
  • Most Recent Events

    • 15 Nov 2016 Status changed from active, no longer recruiting to completed.
    • 25 Aug 2016 Planned End Date changed from 1 Jun 2016 to 1 Dec 2019.
    • 05 May 2016 Planned End Date changed from 1 Mar 2016 to 1 Jun 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top